Rhapsidois also in clinical development for chronic inducible urticaria, food allergy, and hidradenitis suppurativa. Stock.Adobe.comNovartis announced that FDA approved Rhapsido (remibrutinib), an orally administered treatment for Chronic Spontaneous Urticaria (CSU) targeting Bruton’s tyrosine kinase inhibitor (BTKi). 1What is Chronic Spontaneous Urticaria? By blocking the activity of BTK, remibrutinib stops a key pathway of the immune response in CSU. This is an exciting new option that has the potential to help a broad range of patients get fast relief.”Sources